🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "major milestone" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

According to data detailed in a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which uses an injection and a pill. The trial included over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have shared positive views. Access to a single-dose, oral treatment like this is seen as a "game-changer" for public health efforts. This is deemed crucial to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.